Less is More: Active Surveillance In Low-Risk Papillary Thyroid Canc…

Keck School of Medicine of USC

R. Michael Tuttle

ESMO 2024 Summary: Head & Neck Cancer Take Home Messages

2024 ESMO Annual Meeting Insights Hub

P. Bossi

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ASCO® 2024 H&N Highlights: "Key Trial Updates in H&N Cancers"

2024 ASCO® Annual Meeting Insights Hub

N. Saba

ESMO 2024 Summary: Head & Neck Cancer Highlights

2024 ESMO Annual Meeting Insights Hub

N. Saba

Cancer Genomics: Molecular Profile Interpretation 101

Total Health

L. Welch

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ESMO 2024 Insights: 3-Weekly vs. Weekly Cisplatin in High-Risk HNSCC…

2024 ESMO Annual Meeting Insights Hub

M. Tahara

ASCO® 2024 Summary: "News in Head&Neck Cancers"

2024 ASCO® Annual Meeting Insights Hub

P. Bossi

Cancer Screening Molecular Tools

Fengting Yan

Expert Perspectives on Key Trial Insights and Treatment Updates in H…

Yale Cancer Center

B. Burtness

Hypercalcaemia & Hypocalcaemia

Obafemi Awolowo University

D. Soyoye

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

ASCO® 2024 H&N Cancer Highlights: Key Insights From Clinical Trials

2024 ASCO® Annual Meeting Insights Hub

K. Kerrigan

Additional Advances in HNSCC: Immunotherapy & Targeted Treatments

Oncology Data Advisor

D. Wong

2024 Advances in Thyroid Cancer Treatment

GRACE

J. Weiss, S. Patel, S. Sheth

Best of ASCO® Los Angeles 2024: The PATHWay Trial - Adjuvant Pembro …

UCLA Health

D. Wong

ESMO 2024 Insights: Avelumab-Cetuximab-RT vs. SoC in Locally Advance…

2024 ESMO Annual Meeting Insights Hub

M. Tahara

ASCO® 2024 Review: Updates on Metastatic HNSCC

Nebraska Oncology Society

E. Sherman

Common Sense Oncology in Head & Neck Cancers

ecancer

A. D'Cruz